22UA:FRA
BioNTech SE - ADR
€79,70
arrow_upward
+0,76%(+0,60) 1D
15 ຕ.ລ., 13 ໂມງ 50 ນາທີ 40 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€78,65
High
€79,70
Low
€78,60
Mkt. cap
22,27 ຕື້
Avg. vol.
1,41 ພັນ
Volume
42,00
52-wk high
€105,50
52-wk low
€68,00
No. of employees
8 ພັນ
Open
€78,65
High
€79,70
Low
€78,60
Mkt. cap
22,27 ຕື້
Avg. vol.
1,41 ພັນ
Volume
42,00
52-wk high
€105,50
52-wk low
€68,00
No. of employees
8 ພັນ
News stories
From web sources and news partners
ad-hoc-news.de
·
1 ຊົ່ວໂມງກ່ອນ
BioNTech's Pipeline Reckoning: BNT113 Stumble and Insider Sales Keep the Stock 25% Below Its Peak
Pluang
·
17 ຊົ່ວໂມງກ່ອນ
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 ມື້ກ່ອນ
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR